RAPT Therapeutics said the Food and Drug Administration has placed a hold on two trials of the drug zelnecirnon after a patient taking it suffered liver failure. Shares of RAPT were down 63% to $9.49 on Tuesday. The halt has been placed on a Phase 2b trial of zelnecirnon in atopic dermatitis and a Phase 2a trial in asthma, the company said.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles